Introduction
============

Breast cancer is one of the most common malignancies in women. According to statistics, breast cancer accounts for 7--10% of all malignancies and is next only to uterine cancer in women ([@b1-ol-0-0-7143]). The pathogenesis of breast cancer is often related to genetic factors. Pre- and postmenopausal women between 40 and 60 years of age have the highest incidence and tumors are commonly originated in mammary gland epithelial tissue ([@b1-ol-0-0-7143],[@b2-ol-0-0-7143]). Statistical data published by WHO in 2008 indicated that new cases of breast cancer reached 1.38 million/year, ranking second among women. In addition, breast cancer accounted for 23% of new cases of cancer and ranked fifth in the causes of cancer death. Thus, breast cancer remains a serious threat to women\'s health ([@b3-ol-0-0-7143],[@b4-ol-0-0-7143]).

The existing clinical treatments for breast cancer usually have large adverse reactions, not only causing excruciating pain but also seriously reducing the quality of life. Chinese herbs have many advantages in traditional Chinese medicine. Its effective ingredients are characterized by high efficiency and low toxicity, and recently both domestic and foreign scientists have paid more attention to Chinese herbs due to these important advantages. The active ingredients from extracts of Chinese herbs play significant roles in inhibiting cancer cell proliferation, inducing apoptosis, and reducing the adverse effects of chemotherapy and radiotherapy ([@b5-ol-0-0-7143]). In recent years, Chinese herbs have become a hot spot due to minor side effects, anticancer and immune regulatory effects ([@b6-ol-0-0-7143]). Coumarin is a compound with the benzo-α-pyrone nucleus that has many biological activities with broad medicinal value, including anticancer, immune support, antivirus, anti-bacterial, anti-oxidation, antiarrhythmic and anti-osteoporosis ([@b7-ol-0-0-7143]). Fraxetin is a simple coumarin compound and is an active ingredient of traditional Chinese medicine Cortex Fraxini. Fraxetin has received recent attention for its antitumor, anti-oxidation effects, as well as other pharmacological effects ([@b8-ol-0-0-7143]).

Bcl-2 can inhibit cell apoptosis and plays a critical role in the regulation of apoptosis. In addition, Bcl-2 can protect cells from death, improve cell survival, and increase the number of cells ([@b9-ol-0-0-7143]). Bax and Bcl-2 belong to the same family, but Bax promotes apoptosis. Bax antagonizes the apoptosis inhibitory effect of *Bcl-2* gene and directly promotes cell apoptosis by interaction with cells ([@b10-ol-0-0-7143]). Factor-associated suicide (Fas) is a cell death factor that can induce apoptosis, and when Fas combines with the corresponding Fas ligand (FasL) on the cell surface, it activates an intracellular-related apoptotic signaling pathway ([@b11-ol-0-0-7143],[@b12-ol-0-0-7143]).

The aim of the current study was to investigate the effect of fraxetin on the proliferation and apoptosis of human breast cancer cells MCF-7. We examined the mechanism by which fraxetin induces apoptosis. This study lays the foundation for the clinical treatment of breast cancer.

Materials and methods
=====================

### Cell culture

MCF-7 breast cancer cells (Cell Bank, Chinese Academy of Sciences, Shanghai, China) were cultured at 37°C in 5% CO~2~ until 85% confluence was reached. Then, the cells were digested with trypsin and cell suspension was diluted with Dulbeccos modified Eagles medium (DMEM) (Gibco, Carlsbad, CA, USA) containing 10% fetal bovine serum. After cell concentration was adjusted to 2×10^8^/liter, the cells were counted and seeded in culture plates for the subsequent experiments.

### Cell proliferation inhibition rate

Cell proliferation was measured using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay after cells were treated with fraxetin (both from Sigma, St. Louis, MO, USA). MCF-7 cells were seeded in 96-well plates at a concentration of 1×10^5^/ml and each well contained 100 µl. After 24 h, fraxetin was added to 10, 20, 40 and 60 µM final concentrations. The control group was treated without fraxetin. The cells were incubated for 24 and 48 h at 37°C in 5% CO~2~ and then culture medium was changed. MTT (10 µl) was added to each well at a final concentration of 5 mg/ml. After incubating for 4 h, the optical density (OD) at 570 nm was measured by a microplate reader (Bio-Rad Laboratories, Inc., Hercules, CA, USA). The inhibition rate was calculated as: Inhibition rate (%) = (OD value of control group - OD value of experimental group/OD value of control group) × 100%.

### Morphological observation

MCF-7 cells were treated with 20, 40 and 60 µM of fraxetin for 24 h, and the morphological changes were observed and recorded with an inverted microscope (Nikon, Tokyo, Japan).

### 4,6-Diamidino-2-phenylindole (DAPI) staining

MCF-7 cells were seeded in 6-well plates at a density of 1×10^4^ cells/well. After 24 h, the supernatant was suctioned and the cells were cultured in medium containing 20, 40 or 60 µM of fraxetin for 24 h, then washed with pre-cooled phosphate-buffered saline (PBS) 3 times. DAPI solution (1 µg/ml) was added to each well, the cells were incubated at 37°C for 5 min and washed with pre-cooled PBS again. The cells were observed and images were captured using a fluorescence microscope (Nikon) in the dark.

### Fas/FasL mRNA expression by RT-PCR

MCF-7 cells were seeded in 6-well plates at a density of 1×10^4^ cells/well. After 24 h, the supernatant was suctioned and the cells were cultured in medium containing 20, 40 or 60 µM of fraxetin for 24 h, the cells were collected and total RNA was extracted according to the instructions of the RNA extraction kit (Invitrogen, Carlsbad, CA, USA). RNA concentration and purity (A260/A280 \>1.8, indicating pure RNA) were determined by UV-Vis spectrophotometer (Hitachi, Tokyo, Japan). cDNA was obtained via reverse transcription from mRNA according to the instruction of the reverse transcription kit (Invitrogen). The expression of target genes was then detected using cDNA as the template by RT-PCR assay, according to the manufacturer\'s instructions (Invitrogen), and glyceraldehyde 3-phosphate dehydrogenase (*GAPDH*) was used as an internal control. The primer sequences for Fas and FasL (Takara, Dalian, China) are shown in [Table I](#tI-ol-0-0-7143){ref-type="table"}. Amplification conditions were: 95°C for 10 min, 95°C for 15 sec, 60°C for 1 min, with 40 cycles of amplification. The Ct value was automatically calculated using the CFX Manager software (Bio-Rad Laboratories, Inc.), and the relative quantification of gene expression was calculated using the 2^−ΔCt^ method, as per the formula: ΔCt (target gene) = Ct (target gene) - Ct (control gene).

### Bax and Bcl-2 protein expression by western blotting

MCF-7 cells were seeded in 6-well plates at a density of 1×10^4^ cells/well. After 24 h, the supernatant was suctioned and the cells were cultured in medium containing 20, 40 or 60 µM of fraxetin for 24 h. The cells were collected and lysed with cell lysis buffer (Biyuntian Biotechnology Research Institute, Nantong, China), centrifuged for 15 min at high speed and low temperature, and the supernatant was collected. The extracted protein concentrations were determined using a BCA protein quantification kit (Biyuntian Biotechnology Research Institute, Nantong, China). Subsequently, 50 µg protein was separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), and the proteins were transferred to a PVDF membrane. The membrane was incubated in blocking buffer for 1 h at room temperature and primary rabbit anti-huamn polyclonal antibodies against GAPDH, Bax and Bcl-2 (dilution, 1:1,000; cat. nos. 13937-1-AP, 23931-1-AP and 12789-1-AP; Sanying Biotechnology, Wuhan, China) were added and the membrane was incubated overnight at 4°C. After washing the membrane with TTBS, HRP-conjugated goat anti-rabbit polyclonal secondary antibody (dilution, 1:2,000; cat. no. SA00001-2; Sanying Biotechnology) was added and the membrane was incubated at room temperature for 1 h. Enhanced chemiluminescence (ECL) was added to the membrane and blots were developed in the dark. Images were recorded with a gel imaging system (Bio-Rad Laboratories, Richmond, CA, USA). GADPH was used as the internal reference, and the gray-scale values were analyzed and compared.

### Statistical analysis

Data were presented as means ± standard deviations. Data were analyzed by SPSS 17.0 (IBM Corp., Armonk, NY, USA) using one-way ANOVA along with multiple comparison test. P\<0.05 was considered statistically significant.

Results
=======

### Effect of fraxetin on inhibition of MCF-7 cell proliferation

We first examined the ability of fraxetin to inhibit cell proliferation. MCF-7 cells were cultured in medium containing 0, 10, 20, 40 and 60 µM of fraxetin. After 24 h, the proliferation of MCF-7 cells was significantly inhibited in all the groups ([Table II](#tII-ol-0-0-7143){ref-type="table"}). The proliferation inhibition rates were obtained in a dose- and time-dependent manner ([Table II](#tII-ol-0-0-7143){ref-type="table"}). To examine the apoptotic mechanism, 20, 40 and 60 µM of fraxetin were chosen as the drug concentrations and incubation time was 24 h for the subsequent experiments.

### Effect of fraxetin on MCF-7 cell morphology

After MCF-7 cells were cultured for 24 h with 0, 20, 40 and 60 µM of fraxetin, the morphology of cells showed obvious changes. We observed cell shrinkage, decreased cell adherence, reduced cell number, and increased cell death number ([Fig. 1](#f1-ol-0-0-7143){ref-type="fig"}). The changes in morphology exhibited dose-dependence.

### Effect of fraxetin on cell apoptosis

After MCF-7 cells were cultured for 24 h with 20, 40 and 60 µM of fraxetin, DAPI staining showed cell shrinkage and nuclear chromatin condensation, suggesting the occurrence of apoptosis ([Fig. 2](#f2-ol-0-0-7143){ref-type="fig"}). Moreover, the number of apoptotic cells increased with the increasing concentrations of fraxetin.

### Effect of fraxetin on expression of Fas and FasL mRNA

The expression of *Fas* and *FasL* mRNA was significantly increased (P\<0.01) after cells were incubated for 24 h with 20, 40 and 60 µM of fraxetin compared to the control cultured without fraxetin ([Fig. 3](#f3-ol-0-0-7143){ref-type="fig"}).

### Effect of fraxetin on Bax and Bcl-2 protein expression levels

After the cells were cultured for 24 h with 20, 40 and 60 µM of fraxetin, the expression levels of Bax protein were significantly increased compared to the cells cultured without fraxetin (P\<0.01). By contrast, the expression levels of Bcl-2 were significantly decreased in the wells treated with fraxetin ([Fig. 4](#f4-ol-0-0-7143){ref-type="fig"}). The expression levels of Bax and Bcl-2 changed in a dose-dependent manner.

Discussion
==========

The increasing incidence of breast cancer makes it a serious threat to the lives of women and to their quality of life. Breast cancer cells are prone to drug resistance and adverse reaction to first-line chemotherapy drugs are obstacles to breast cancer treatment. Therefore, the choice of targeted therapy, the rationalization of individual treatment regimen, and the harm reduction in therapeutic drugs have been primary aims for breast cancer treatment ([@b13-ol-0-0-7143]). At present, drugs used for targeted therapy are lacking; therefore, effective drugs with low toxicity that are cost-effective have become a societal priority.

In some tumors, the upregulation of Bcl-2 protects cells from death or prolonged lifespan ([@b14-ol-0-0-7143]), indicating that Bcl-2 is critical for tumor survival. When Bcl-2 forms homodimers, it inhibits apoptosis. By contrast, Bax promotes apoptosis when its expression increases and binds Bcl-2 forming heterodimers or when Bax forms homodimers ([@b15-ol-0-0-7143]). Additionally, Bcl-2 downregulation induces apoptosis in multiple myeloma ([@b16-ol-0-0-7143],[@b17-ol-0-0-7143]). The abnormal expression of Fas/FasL is associated with a variety of diseases, including immune system diseases, tumor immunity, and transplantation immunity ([@b18-ol-0-0-7143]). The Fas/FasL signaling pathway also plays an important role in tumor inhibition: Fas expression is downregulated or lost in malignant tumor cells and when tumor cells are transformed, Fas is almost completely absent ([@b19-ol-0-0-7143]).

In the present study, we have shown that fraxetin significantly inhibited the proliferation of MCF-7 cells and induced morphological changes, including cell shrinkage and nuclear chromatin condensation. Additionally, fraxetin upregulated the expression of *FasL* and *Fas* mRNA. A positive expression of Fas found in non-small cell lung cancer tissues and normal tissues was 46.7 and 100%, respectively ([@b20-ol-0-0-7143],[@b21-ol-0-0-7143]). Tumor cells avoid Fas/Fas-mediated apoptosis by downregulating the expression of Fas and preventing binding to its ligand FasL. Findings of that study are similar to those of the present study, further confirming that fraxetin can activate the apoptotic pathway and induce apoptosis of MCF-7 cells by upregulating the expression of *Fas* and *FasL* mRNA. Furthermore, fraxetin induced the expression of Bax while the expression of Bcl-2 was decreased, further inducing tumor cell apoptosis. The study by Xi *et al* ([@b22-ol-0-0-7143]) showed that carnosol induced Bax upregulation in leukemic cells and downregulation of Bcl-2 protein by 34--53%.

In conclusion, the present study has demonstrated that fraxetin inhibits the proliferation of the MCF-7 breast cancer cell line and induces apoptosis of MCF-7 cells. The induction of apoptosis may be achieved by upregulating FasL, Fas and Bax and downregulating Bcl-2. In conclution, our results provide experimental support for the therapeutic effect of fraxetin on breast cancer.

![Effect of fraxetin on MCF-7 cell morphology. Changes of MCF-7 cell morphology, including cell shrinkage, decreased cell adherence, reduced cell number, and increased cell death number, were observed after treating cells with different concentrations of fraxetin for 24 h. Morphological changes exhibited a significant dose-dependency.](ol-14-06-7374-g00){#f1-ol-0-0-7143}

![Effect of fraxetin on MCF-7 cell apoptosis. After MCF-7 cells were treated with different concentrations of fraxetin for 24 h, cell shrinkage and chromatin condensation were observed indicating cell apoptosis.](ol-14-06-7374-g01){#f2-ol-0-0-7143}

![Effect of fraxetin on the expression of factor-associated suicide (*Fas*) and Fas ligand (*FasL*) mRNA. Compared with the control group, the expression levels of *Fas* and *FasL* mRNA were significantly increased in fraxetin-treated groups, \*\*p\<0.01.](ol-14-06-7374-g02){#f3-ol-0-0-7143}

![Effect of fraxetin on the expression levels of Bax and Bcl-2 in MCF-7 cells. (A) Bcl-2 and (B) Bax protein expression. Compared with the control group, the expression level of Bcl-2 was significantly decreased, while that of Bax protein was significantly increased, \*\*p\<0.01.](ol-14-06-7374-g03){#f4-ol-0-0-7143}

###### 

Primer sequences for *Fas*/*FasL*.

  Gene      Primer sequences
  --------- -------------------------------------
  *Fas*     F: 5′-GGCATCTGGACCCTCCTACCTCTG-3′
            R: 5′-CCTTGGAGTTGATGTCAGTCACTTGG-3′
  *FasL*    F: 5′- GGCCTGTGTCTCCTTGTGAT-3′
            R: 5′-TGCCAGCTCCTTCTGAAGTA-3′
  *GAPDH*   F: 5′-ATGGCACCGTCAAGGCTGAG-3′
            R: 5′-GCAGTGATGGCATGGACTGT-3′

Fas, factor-associated suicide; FasL, factor-associated suicide ligand; F, forward; R, reverse.

###### 

Inhibitory effects of fraxetin on MCF-7 cell proliferation (mean ± SD).

        Cell proliferation inhibition rate (%)                    
  ----- --------------------------------------------------------- ---------------------------------------------------------
    0   0                                                         0
  10    9.25±0.12^[a](#tfn2-ol-0-0-7143){ref-type="table-fn"}^    12.32±1.13^[a](#tfn2-ol-0-0-7143){ref-type="table-fn"}^
  20    18.13±0.31^[a](#tfn2-ol-0-0-7143){ref-type="table-fn"}^   42.32±2.31^[a](#tfn2-ol-0-0-7143){ref-type="table-fn"}^
  40    35.67±1.32^[a](#tfn2-ol-0-0-7143){ref-type="table-fn"}^   58.22±2.28^[a](#tfn2-ol-0-0-7143){ref-type="table-fn"}^
  60    46.23±1.56^[a](#tfn2-ol-0-0-7143){ref-type="table-fn"}^   62.17±2.02^[a](#tfn2-ol-0-0-7143){ref-type="table-fn"}^

P\<0.01 vs. the control group. SD, standard deviation.

[^1]: Contributed equally
